Hepatitis C (chronic) - ledipasvir-sofosbuvir [ID742]: committee papers 1
Table of Contents
01 - Pre-Meeting Briefing prepared by NICE
02 - Submission from the technology manufacturer - Gilead Sciences
03 - NICE request to the Company for clarification on their submission
04 - Appendix to the clarification letter
05 - Company clarification response
06 - Consultee submission - Hepatitis C Trust
07 - Consultee submission - Liver for Life
08- Consultee submission - British Society for Gastroentology
09- Clinical expert personal perspective - Cramp
10- Clinical expert personal perspective - Harris
11- Patient expert personal perspective - Hall
12 - Evidence Review Group report prepared by Scharr
13 - Evidence Review Group report Factual error check
14 - Erratum to the Evidence Review Group report
15 - Addendum to the Evidence Review Group Report
16 - Addendum two to the Evidence Review Group Report
Hepatitis C (chronic) - ledipasvir-sofosbuvir [ID742]: committee papers 1
19 May 2015 (11.5 Mb 10 sec) |
This page was last updated: 23 July 2015